Explains

1
Explains

• The Joint Research Councils
• Bio4EU Report
• Dr. Johan Vanhemelrijck
• Secretary General of EuropaBio

2
First GlanceIs Europe doing well?

• Healthcare Biotech
• The number of biopharmaceuticals on the market
  has more than doubled in the last ten years.
• Agricultural Biotech
• Modern Biotechnology is related to up to 20 of
  the input sectors turnover.
• Industrial Biotech
• The EU produces about 75 of enzymes worldwide.

3

• EuropaBio, the European Association for
  Bioindustries, has 78 direct corporate members,
  12 associate members and 5 bioregions as well as
  25 national biotechnology associations
  representing some 1800 small and medium sized
  enterprises involved in research and development,
  testing, manufacturing and distribution of
  biotechnology products.
• www.europabio.org

4
What is Bio4EU?

• The Joint Research Councils Bio4EU Study
• A comprehensive socio-economic impact study of
  biotechnology in Europe.
• Input for the Mid-Term Policy Review on the EUs
  Life Science and Biotechnology Strategy (2002).
• Published on 20 April 2007 at the Bio4EU
  Symposium in Brussels.

5
Bio4EU in-Depth

• Biotechs Contribution to EU Policy Goals
• Survey of the Biotech industry
• Healthcare
• Agriculture
• Industrial
• Biotech RD
• Biotech Employment
• The EU policy based on Bio4EU
• EuropaBios Diagnosis

6
EU Policy Goals Biotech

• Competitiveness
• Biotech enhances the efficiency of production
  processes.
• Economic Growth
• Biotech enables the provision of new and improved
  products.
• Employment
• Biotech jobs appear to be higher qualitatively
  and more productive.
• Overall contribution 1.56 to the EUs Gross
  Value Added (GVA).

7
Healthcare Biotech

• Source Bio4EU Draft Final Analysis report

8
Biopharmaceuticals
Healthcare

• Biopharmaceutical companies rose from 37 (1996)
  to 143 (2005).
• 78 of EU biotech products are biopharmaceuticals.
  
• Biopharmaceuticals hold a 9 share of the EU
  pharmaceutical market.
• Growth rates in biopharmaceuticals are twice as
  high as non-biotech.

9
Biopharmaceuticals
Healthcare

• Examples include
• Cancer treatment (antibodies)
• Diabetes (insulin)
• Multiple sclerosis (innovative treatments)
• Gaucher's disease (enzyme replacement).

10
Vaccines
Healthcare

• Safety, e.g. biotech vaccines made with only the
  proteins of pathogens which trigger the immune
  reaction.
• The revenues for recombinant vaccines in the EU
  have grown from EUR 65 million (1996) to EUR 259
  million (2005).
• Examples include
• Hepatitis B vaccines

11
Diagnostics
Healthcare

• In vitro diagnostics (IVD) are methods for
  testing specimens taken from the body
• Biotech IVD consist of about 30 of turnover from
  all IVD in the EU in 2005.
• Innovative examples include
• HIV detection using nucleic-acid-based tests
• Cardiac diagnostic assays to detect biomarkers
  associated with heart attacks.

12
Outlook
Healthcare

• Biotech offers healthcare
• unique therapeutic and diagnostic solutions
• unlimited supplies of potentially safer products
  
• superior therapeutic and diagnostic approaches
• the potential for cost reduction.

13
Agri-food Biotech
Agri-Food
Agri-food sub-sectors using biotech

• Biotech represents 2 of the Agri-food sector
• Source Bio4EU Draft Final Analysis report

14
Agri-food Biotech
Agri-Food

• Molecular markers are applied in research in
  almost all plant-related sectors for hybrid
  variety development.
• Micropropagation, for cloning identical offspring
  in large numbers, is used for the multiplication
  of ornamental plants.
• 60 is used for propagating orchids commercially.

15
Agri-food Biotech
Agri-Food

• Genetic Modification - only 2 Bt maize GM crops
  have been approved for cultivation in the EU.
• Studies in Spain show an average increase in
  gross margin of 85 Euro per ha, this is 12
  higher than non-BT maize production.
• Economic benefits vary from region to region
  depending on insect pressure and other factors.

16
Agri-food Biotech
Agri-Food

• The EU is falling behind the rest of the world in
  GM crop adoption
• SourceBio4EU Draft Final Analysis report

17
Agri-food Biotech
Agri-Food

• Biotech is used in veterinary and food
  diagnostics, such as in the detection of BSE
  Salmonella.
• For BSE, biotech provides the only method for the
  rapid processing of samples and diagnosis, to
  comply with EU legislation, reducing the risk of
  contamination and increasing consumer trust in
  beef.

18
Agri-food Biotech
Agri-Food

• Other examples include
• diagnostic veterinary vaccines, for pseudorabies
  eradication
• enzymes for food production, for in fruit juice
  production.

19
Outlook
Agri-Food

• Agri-food biotech can
• increase crop efficiency
• monitor and control some of the most important
  animal-to-human disease transfers and food safety
  concerns.
• reduce costs of applications in the agri-food
  industry
• real benefits for public health.

20
Industrial Biotech
EU
The EU has 75 enzyme producing companies
Source Bio4EU Draft Final Analysis report
21
Industrial Biotech
Industrial

• About 45 of all manufacturing sectors use modern
  biotechnology.
• Biotech contributes to sustainability by
• Reducing the levels of chemicals and energy for
  input.
• Reducing emissions into the air or water.
• Reducing the consumption of water in
  manufacturing.
• Reducing the ecological footprint of industry.

22
Enzymes
Industrial

• Currently limited to specific processes and
  enzyme production for individual steps in the
  manufacturing production process.
• Examples of enzyme use include
• textile finishing and de-sizing cotton
• pulp bleaching for pulp and paper manufacturing

23
Enzyme uses
Industrial

• detergents for laundry and automatic dishwashers
• polymers are biotech-based in some chemical
  products
• antibiotics, amino acids and drug compounds have
  biotech production processes.

24
BioFuels
Industrial

• 100 replacement of gasoline with bioethanol
  would lower GHG emissions by around 4.
• Biofuels offer environmental benefits
• due to the switch to renewable input materials
• due to lower energy demand from industrial
  processes.

25
BioFuels
Industrial

• Biofuels, especially bioethanol, have potential
  to diversify energy sources, increase renewable
  energy sources and reduce GHG emissions.
• Research is focusing bioethanol, from non-food
  feedstock or biomass.
• Biotech processes are being researched for the
  production of other biofuels like Biodiesel and
  Biobutanol.

26
Outlook
Industrial

• Industrial Biotech
• increases labour productivity by 10 to 20
  compared with conventional processes
• reduces energy and water consumption and
  emissions, including greenhouse gases
• offers more sustainable methods to produce
  everyday necessities from energy to clothing.

27
Biotech RD

• The EU is strong in terms of researchers and
  biotech research centres.
• However, the EUs capacity to apply this
  knowledge to products that lead to commercially
  viable businesses is lower than in the USA.

28
Biotech Employment

• Biotech-related processes
• Create of higher qualified jobs.
• However,
• There is limited data availability and
  difficulties in including indirect employment
  effects.
• Some newly generated biotech jobs take the place
  of existing ones.

29
The EU policy priorities from Bio4EU

• The EU Commissions action plan
• Promote research and market development.
• Facilitate knowledge transfer and innovation from
  the science base to industry.

30
The EU policy priorities from Bio4EU

• Encourage informed societal debates.
• Ensure a sustainable contribution of modern
  biotechnology to agriculture.
• Improve the implementation of the legislation at
  Member State level.

31
Diagnosis

• The Bio4EU Study is a welcome and an extensive
  contribution to the Mid-Term Policy Review.
• The refocused actions proposed by the Commission,
  as a result of the Bio4EU Study, are an important
  step towards building the bio-economy.

32
Diagnosis

• However, it is essential that the important
  information in the Bio4EU Study not go to waste.
• There is a lack of implementation of the EU
  biotech strategy by a number of Member States.
• The new action plan for biotechnology should to
  be implemented evenly and coherently throughout
  Europe.

33
Diagnosis

• Ministers must realise that they are the key
  solution to reduce the fragmentation by
  implementing the strategy in a coherent and
  timely manner. This will take the science out of
  the labs and bring it to society, helping to meet
  our needs be they medical, agricultural,
  industrial or environmental.

34

• Thank you
• To learn more about EuropaBio
• www.europabio.org

35
Citations

• JRC Bio4EU Reports
• Synthesis Report - Consequences, Opportunities
  and Challenges of Modern Biotechnology for Europe
• Analysis Report - Contributions of modern
  biotechnology to European policy objectives (DG
  JRC/IPTS) - Draft Final Version, 31 January 2007
• Both reports can be found at http//bio4eu.jrc.es/
  
• EU Commission Documents
• EU puts emphasis on innovation in the field of
  biotechnology EU Commission Press Release of
  11/04/2007 http//europa.eu/rapid/pressReleasesAct
  ion.do?referenceIP/07/484formatHTMLaged0lang
  uageENguiLanguageen